LeonaBio Reports Full Year 2025 Financial Results and Provides Business UpdateAcquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business OfficerBrings more than 25 years of biopharma business development and corporate strategy expertise
